Menu Back to Event-Details

Topic I. How Can We Enable Clinical Research in Europe Further?

Track:
How Can We Enable Clinical Research in Europe Further?

Day & Time:
April 18, 4:00PM - 5:30PM (Central Europe Standard Time)

Session Number:
S0903

Level:
Advanced

Type:
Session

Title:
Topic I. How Can We Enable Clinical Research in Europe Further?

Chair(s):
Mireille Muller, DrSc, PhD, MSc
Regulatory Policy Director
Novartis Pharma AG, Switzerland

Description:
Multiple trial design options are required to increase efficiency in clinical trial conduct in increasingly complex conditions and smaller populations while maintaining scientific value and data quality to meet the wants of all stakeholders.

Presentation(s) & Speaker(s):
From Adaptive Designs to the Trial Designs of the Future
Michael Krams
Vice President, Quantitative Sciences
Janssen Pharmaceuticals, Inc., United States

Immuno-Oncology: coping with complexities of development at an unprecedented breadth and scale.
Sacha Wissink, PhD
Exec. Director Regulatory Affairs EMEA
MSD, Netherlands

Empowering Phase II Clinical Trials To Reduce Phase III Failures
Daniele De Martini, PhD
Associate Professor
Milano-Bicocca University, Italy